Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From (For) Operating Activities
Net income	$ 146.1	$ 131.0	$ 119.6
Adjustments to derive cash flows:
Depreciation and amortization	396.5	423.6	444.8
Gain on sale of business	(71.7)	0.0	0.0
Share-based compensation	52.2	37.7	43.8
Impairment charges	184.5	224.4	47.5
Asset abandonments	11.0	0.0	0.0
Change in financial assets	(22.1)	(188.7)	24.9
Loss on extinguishment of debt	0.2	0.5	135.2
Restructuring charges	26.3	21.0	61.0
Deferred income taxes	(43.9)	(17.9)	(48.9)
Amortization of debt premium	(4.4)	(8.1)	(22.4)
Other non-cash adjustments, net	26.6	(11.1)	(2.7)
Subtotal	701.3	612.4	802.8
Increase (decrease) in cash due to:
Accounts receivable	(140.7)	21.0	3.2
Inventories	(67.0)	(98.6)	(16.0)
Accounts payable	17.0	28.8	(39.6)
Payroll and related taxes	(3.7)	(34.5)	(27.4)
Accrued customer programs	(48.6)	25.5	34.6
Accrued liabilities	(23.2)	(20.9)	(47.8)
Accrued income taxes	(74.5)	68.1	(6.1)
Other, net	27.2	(8.8)	(4.8)
Subtotal	(313.5)	(19.4)	(103.9)
Net cash from operating activities	387.8	593.0	698.9
Cash Flows From (For) Investing Activities
Proceeds from royalty rights	2.9	13.7	87.3
Acquisitions of businesses, net of cash acquired	(747.7)	0.0	(0.4)
Asset acquisitions	(149.1)	(35.6)	0.0
Purchase of investment securities	0.0	(7.5)	0.0
Proceeds from the Royalty Pharma contingent milestone	250.0	0.0	0.0
Additions to property, plant and equipment	(137.7)	(102.6)	(88.6)
Net proceeds from sale of business	182.5	5.2	154.6
Proceeds from sale of the Tysabri® financial asset	0.0	0.0	2,200.0
Other investing, net	3.0	0.0	(14.8)
Net cash from (for) investing activities	(596.1)	(126.8)	2,338.1
Cash Flows From (For) Financing Activities
Borrowings (repayments) of revolving credit agreements and other financing, net	0.5	(4.4)	6.8
Issuances of long-term debt	600.0	431.0	0.0
Payments on long-term debt	(476.0)	(482.5)	(2,611.0)
Premiums on early debt retirement	0.0	0.0	(116.1)
Deferred financing fees	(1.0)	(2.4)	(4.8)
Issuance of ordinary shares	0.9	1.3	0.7
Repurchase of ordinary shares	0.0	(400.0)	(191.5)
Cash dividends	(112.4)	(104.9)	(91.1)
Other financing, net	(10.2)	(10.0)	2.3
Net cash from (for) financing activities	1.8	(571.9)	(3,004.7)
Effect of exchange rate changes on cash and cash equivalents	9.7	(21.9)	24.1
Net increase (decrease) in cash and cash equivalents	(196.8)	(127.6)	56.4
Cash and cash equivalents, beginning of period	551.1	678.7	622.3
Cash and cash equivalents, end of period	354.3	551.1	678.7
Cash paid/received during the year for:
Interest paid	136.8	133.8	187.6
Interest received	15.1	5.0	9.3
Income taxes paid	136.2	144.2	186.9
Income taxes refunded	$ 28.0	$ 5.1	$ 3.6